Abstract
Peptide-based vaccines aimed at the induction of effective T-cell responses against established tumors have not been successful in clinic and require the use of new adjuvants. One of those is a new adjuvant in which gangliosides are incorporated into the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). In a preclinical model of human papillomavirus HPV16-induced cervical cancer we show that vaccination with HPV 16 E7 derived minimal CTL peptide and VSSP protects mice against tumor challenge, induces regression of established tumors and produces E7-specific CD8+ T-cell responses.
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Animals
-
Cell Line
-
Humans
-
Immunotherapy
-
Mice
-
Mice, Inbred BALB C
-
Papillomaviridae / drug effects*
-
Papillomaviridae / immunology
-
Papillomavirus Infections / immunology
-
Papillomavirus Infections / therapy*
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / immunology*
-
Proteolipids / administration & dosage*
-
Proteolipids / immunology
-
Tumor Virus Infections / immunology
-
Tumor Virus Infections / therapy*
-
Vaccines, Subunit / administration & dosage
-
Vaccines, Subunit / immunology
Substances
-
Adjuvants, Immunologic
-
Peptide Fragments
-
Proteolipids
-
Vaccines, Subunit
-
proteoliposomes